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Abstract: Pharmacists report being less confident in their knowledge of direct acting oral
anticoagulants (DOACs) than of vitamin K antagonists, which may influence their ability to detect
and manage complications arising from DOAC use. In a mystery shopper study, patient agents
were sent into community pharmacies with symptom or product-related requests related to common
complications that might arise during treatment with oral anticoagulants, with each visit being
assessed for the preferred outcome. Only 10/41 (24.4%) visits resulted in the preferred outcome.
A complete history-taking process, obtaining a medical history, patient characteristics and pharmacist
involvement were strong predictors of the preferred outcome being achieved. The preferred outcome
was not consistently achieved without pharmacist involvement. The potential for strategies that
support comprehensive pharmacist involvement in over-the-counter requests should be considered
to ensure the provision of optimal care to patients taking high-risk medications such as DOACs.
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1. Introduction
Oral anticoagulation is required in patients with atrial fibrillation (AF) due to the increased risk
of thromboembolic events, mainly stroke [1,2]. Previously, vitamin K antagonists (VKAs) were the
only class of oral anticoagulant (OAC) medication available; however, in more recent years direct oral
anticoagulants (DOACs) have become available in Australia [3]. DOACs quickly became the first-line
therapy for AF once they entered the Australian market in 2013, because of their superior safety and
effectiveness [4].
Effective patient education in the use of OACs has been reported to improve outcomes in
patients with AF [5–7]. Patients taking DOACs have been reported to have sub-optimal knowledge
regarding their anticoagulant therapy relative to the level of knowledge observed among patients
taking warfarin [7]. Potential explanations for this include fewer healthcare professional interactions
and less intensive counselling when commencing the medication [7]. Adverse effects are common
in patients taking OACs and, due to knowledge gaps, patients may rely on pharmacists and other
healthcare professionals to identify and manage them [7,8]. Pharmacists have reported being less
confident in their knowledge of DOACs than VKAs [9]. This might be hypothesised to negatively
impact the education provision to patients taking DOACs and potentially lead to a suboptimal detection
rate of OAC adverse effects.
Pharmacists promote and ensure the quality use of medicines for their patients [10]. It follows that
pharmacists are expected to counsel patients on prescribed medication as well as for over-the-counter
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(OTC) medications based on the patients’ needs [10,11]. Structured patient education from pharmacists
improves patient knowledge and adherence [12]. When presented with an OTC or minor ailment request,
pharmacists are encouraged to employ protocols such as WHAT/STOP/GO [13] to assist in ensuring
that they obtain relevant information from the patient, such as medical history, current medications,
allergies, details of the presenting complaint and any self-management, before making a clinical
decision [13].
Pharmacists are in a key position to provide medication knowledge to patients with AF.
Interestingly, pharmacists have been observed to take a different approach when counselling patients
on DOACs compared to VKAs [9]. They were less likely to use a checklist to ensure all appropriate
points were covered [9], and less confident in their knowledge, skills and access to resources on
DOACs [14]. They reported lacking confidence in their ability to manage bleeding and bruising as
potential adverse effects, and reported more confidence in general areas of management such as the
indication of the medication [14]. These studies did not report on pharmacist knowledge of OACs.
It is currently unknown whether this impacts the advice they provide to patients. It is important to
identify whether pharmacists can effectively identify potential DOAC-related complications and make
appropriate recommendations to improve the care of people with conditions requiring an OAC.
The aim of this study was to investigate the quality of advice provided by pharmacy staff when
managing scenarios involving DOACs. More specifically, our objectives were to assess the ability of
pharmacists to appropriately manage community pharmacy presentations involving DOACs where
patient agent actors presented on behalf of patients with symptoms of potential adverse events or
drug interactions, and to identify elements of the history-taking process that were associated with the
achievement of the preferred outcome of each scenario.
2. Materials and Methods
This prospective study utilised mystery shoppers (MSs) to investigate pharmacists’ ability to
appropriately manage scenarios involving potential DOAC-related complications. Three MSs were
enlisted to act out one of three cases in each participating community pharmacy. Fourth-year Bachelor
of Pharmacy students were invited to participate in this project to act as MSs on behalf of older relatives.
Each MS received a small incentive for each pharmacy they visited. Each MS underwent a one-hour
training session to familiarise themselves with the cases before visiting the pharmacies. The session
included role-playing as both the mystery shopper and as the pharmacist. MSs were instructed to
practice further over the following week, and were then approved to commence pharmacy visits.
Each MS was given a recording device to record the interaction, if the community pharmacy allowed it.
Community pharmacies were sent an invitation letter to participate in the study (n= 48). We aimed
to recruit ten to 20 participating community pharmacies, based on previous MS research [15,16].
A follow-up phone call was made to each community pharmacy to answer any questions about
the study. Each pharmacy received a small monetary gift as well as a de-identified summary of their
results relative to other participating pharmacies. The pharmacist in charge or manager was required
to sign a consent form on behalf of the pharmacy to participate. They also had to choose whether
they would allow recording devices into the pharmacy. Informed consent was obtained from all staff
members in each pharmacy, including consent to being recorded. Pharmacies that did not consent to
be recorded were still able to participate in this study.
Each case was designed to target an area of a known knowledge deficiency in patients taking
DOACs based on previous research [6]. The areas targeted included a potential drug–drug interaction
(rivaroxaban and St John’s Wort), a potential adverse effect of dabigatran (dyspepsia), and a potential
adverse effect of apixaban (extensive bruising) [7]. Each case was developed through the collaborative
effort of the researchers. Once they were completed, the cases were sent to two clinical pharmacy
experts for validation, and minor adjustments were based on their recommendations.
Each MS was given one case to act out in each community pharmacy. Therefore, each MS made
14 visits of a total of 42. The MSs were instructed upon their visit to approach the dispensary and
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start the case irrespective of whether they were talking to a pharmacist or pharmacy assistant. If the
pharmacy had consented to being recorded, the MSs began the recording outside the pharmacy and
concealed the device on their person. If a product was recommended, the MS made it known that they
were a MS at the conclusion of the interaction. No items were purchased during this investigation.
Upon conclusion of the visit, the MS exited the pharmacy and immediately completed a data
collection form. The assessment forms had two sections. One section focused on the history-taking
undertaken by the pharmacist (or assistant), including, for example, who the patient was, previous
actions undertaken to address the health problem, the symptoms they were experiencing and medical
and medication histories. The second section focused on the advice and counselling received by the MS,
for example, if the pharmacy staff member identified the potential issue and explained it to the MS.
Additional information was also documented, such as what product was recommended (if applicable),
whether the MS was assisted by a pharmacist or pharmacy assistant or if they referred the patient to
a general practitioner (GP). The MS marked each assessment point with either a ‘yes’ or a ‘no’ and
recorded additional information that they deemed relevant in an empty section. The data collection
form and recording, if applicable, were given to research staff at the earliest possible convenience.
Data collection occurred over a four-week period with regular communication between the MSs
and research staff. The MSs were required to communicate with each other to avoid visiting the same
pharmacies at similar times. A member of the research team was present at the first visit for each MS
and waited outside the pharmacies. This allowed the MSs the opportunity to address any queries or
questions about the interaction.
The recordings were compared to the data collection forms for consistency, and then the data
were entered into a Microsoft Excel (Microsoft, Redmond, DC, USA) spreadsheet. Each community
pharmacy was assigned a study number and any information that could identify the pharmacy was
removed and stored separately. The data were subsequently converted to Jamovi (v1.0.7, Jamovi,
Sydney, Australia) for analysis. Aspects of history-taking such as medical history, previous medications,
age/gender, lifestyle and if they had tried anything for the condition were investigated in all three cases.
Each case was then investigated individually for the appropriate counselling points and if the preferred
outcome was achieved.
The primary outcome of interest was defined as whether a visit resulted in the preferred outcome
being reached (see Table 1). The Fisher’s exact test was performed to investigate whether pharmacist
involvement in the interaction, aspects of history-taking and a complete history-taking process were
associated with the achievement of the preferred outcome. P < 0.05 was considered statistically
significant for all analyses.
This study was approved by the Tasmanian Social Sciences Human Research Ethics Committee
on the 14 March 2019 (ref no. H0017868). This work was conducted in accordance with the Declaration
of Helsinki.
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Table 1. Summary of mystery shopper (MS) case scenarios, including the preferred outcome for each scenario.
DOAC-Related
Problem Scenario Patient
Duration of
Symptoms Symptoms Self-Management Medical History
Current
Medications
Preferred Outcome (All Points
Must Be Met)
Dyspepsia
Patient agent presents
with a request to
treat dyspepsia
55+ year old female 2 weeks
“Heartburn” typically
worse at breakfast and
dinner
No blood in stools or
vomiting
Antacid PRN
Atrial fibrillation
(diagnosed 2 weeks ago)
Hypertension
Diabetes
Dabigatran
Atenolol
Amlodipine
Metformin
Rosuvastatin
(i) Identification of dabigatran
as a potential cause of
the symptoms;
(ii) Appropriate management
advice provided (short-term
treatment, lifestyle advice
or referral);
(iii) Instructions to visit the
general practitioner if
symptoms persist.
Extensive bruising
around body
Patient agent presents
requesting arnica cream 75+ year old female Recent onset
Non-specific bruising
across body No
Atrial fibrillation
(diagnosed 1 year ago)
Hypertension
Apixaban
Metoprolol
Amiodarone
Rosuvastatin
(i) Identification of apixaban as
a potential cause of
the bruising;
(ii) General practitioner referral.
Rivaroxaban +
St John’s Wort
interaction
Patient agent presents
requesting St John’s Wort 65+ year old male
A couple of
months
Visibly
down—recommended by
friend
No
Atrial fibrillation
Cardioversion—4 months ago
Hypertension
Rivaroxaban
Perindopril
(i) Identification of the
potential interaction;
(ii) No sale;
(iii) General practitioner referral.
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3. Results
Of the 48 pharmacies contacted, 45.8% (n = 22) expressed interest. Fourteen of these pharmacies
consented to participate (69.5%), nine of whom also consented to being recorded (see Figure 1). Each MS
conducted 14 visits leading to a total of 42 visits. Data from 41 visits were eligible for analysis, with one
visit being excluded due to the pharmacy not stocking the requested product (St John’s Wort). One error
was identified between the audio recordings and the MS-reported data in this study, which were
corrected based on the audio recording prior to analysis.
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3.1. Pharmacy Characteristics
Eleven of the 14 pharmacies (78.5%) belonged to a multistate chain, while the other three
were local independent pharmacies. Six (42.8%) pharmacies were located in a shopping strip,
three (21.4%) were located in a shopping centre or mall and the remaining five (35.7%) pharmacies
were stand-alone premises.
3.2. Primary Outcome
The preferred outcome was achieved in 24.4% (n = 10) of all visits. Table 2 shows the proportion
of visits that resulted in the preferred outcome by scenario.
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Table 2. Results for preferred outcome by scenario.
Scenario Visits Eligible for Analysis (n) Percentage (%) of Visits thatReached the Preferred Outcome
Dyspepsia 14 7.14% (n = 1)
Bruising 14 50.0% (n = 7)
Drug interaction 13 15.3% (n = 2)
Total 41 24.4% (n = 10)
3.3. Factors Associated with the Preferred Outcome
The impact of aspects of the history-taking process on the preferred outcome are shown in
Table 3. Obtaining the patient’s medication history, medical history, patient characteristics and a
complete history-taking process were all significant predictors of the preferred outcome being achieved.
The most common reason for the preferred outcome not being attained was failure to obtain all the
relevant information (n = 34, 82.9% of cases). The patients’ current medications were not requested
in 48.8% (n = 20) of cases, and thus the pharmacy staff involved were not aware that the patient was
taking a DOAC. Of the interactions that did include a request for the patient’s current medications,
52.4% (n = 11) of cases failed to reach a preferred outcome.
Table 3. Associations between aspects of history-taking and achievement of the preferred outcome.
Variable
Number (%) of Interactions Where Relevant History Obtained
p
Total (n = 41) Preferred OutcomeAchieved (n = 10)
Preferred Outcome not
Achieved (n = 31)
Medication history 21 (51.2%) 10 (100%) 11 (35.5%) <0.001
Medical history 11 (26.8%) 8 (80%) 3 (9.6%) <0.001
Lifestyle 2 (7.4%) * 0 (0%) 2 (6.5%) 0.60
Patient characteristics
(age/gender) 6 (12.2%) 5 (50%) 1 (3.2%) <0.001
Duration of symptoms 7 (17.1%) 1 (10%) 6 (19.4%) 0.30
Tried anything before 18 (43.9%) 7 (70%) 11 (35.5%) 0.08
Complete history-taking process 7 (17.1%) 6 (60%) 1 (3.2%) <0.001
* n = 27 as it only applied to two cases.
3.4. Interactions
Of the 41 MS visits to the community pharmacies, 38.1% (n = 16) involved interaction with a
pharmacist, either by direct approach from a pharmacist, referral from the assistant to the pharmacist
or through the assistant communicating information to the pharmacist. The remaining 61.0% (n = 25)
of MS visits only involved pharmacy assistants who handled the interaction entirely by themselves,
with no pharmacist involvement. Of the 25 interactions handled by pharmacy assistants alone,
only 4.0% (n = 1) achieved the preferred outcome. Of the 16 interactions involving a pharmacist,
56.3% (n = 9) achieved the preferred outcome. There was a statistically significant association between
pharmacist involvement in the interactions and obtaining the preferred outcome (p < 0.001).
4. Discussion
Only 1 in 4 visits resulted in the preferred outcome. Pharmacist involvement, a complete
history-taking process, and enquiring about medication history, medical history and patient
characteristics were all associated with the preferred outcome being achieved. Almost 60% of
visits with pharmacist involvement achieved the preferred outcome, while the preferred outcome was
only achieved in one visit where a pharmacist was not involved.
Overall, this study highlights the importance of pharmacist involvement in presentations
to community pharmacies. The underlying issues identified could potentially have result in
suboptimal patient outcomes in practice. When investigating factors that contributed to the results,
the history-taking process of most visits was suboptimal. A complete history-taking process was
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conducted in approximately 1 in 6 visits. Many interactions were conducted without the full patient
history, with the medication history being requested in just over half of the visits. Therefore, in many
cases, the pharmacist or pharmacy assistant conducted the interaction without the knowledge the
patient was taking a DOAC. These results highlight the importance of a thorough history-taking
process, and the need to be more cautious when managing simple treatment requests. These requests
(involving OTC and herbal products) may be seen as involving safe medications, potentially leading
to pharmacists and especially pharmacy assistants not taking a thorough history. These results
highlight a potential need for pharmacy assistants to receive further training in effectively obtaining
clinically relevant information and referring patients to the pharmacist for further consideration when
prescription medications are involved.
This is the first prospective study into the quality of education provision provided by pharmacists to
patients surrounding DOAC drug interactions, dyspepsia and bruising. Despite being the first study of
its kind, many of the findings are consistent with previous research. The results highlight the importance
of obtaining an appropriate patient history that is consistent with previous research that demonstrates
an association between an increased number of information gathering questions and reaching an
appropriate outcome [15,17,18]. The results also highlight the importance of pharmacist involvement
in patient interactions, with their involvement being a significant precursor to a preferred outcome
being reached. This is consistent with previous research [15,19]. Encouraging pharmacist participation
in patient interactions through medication scheduling has been shown to impact the outcome for
patients [20], while formal, protocol-driven Minor Ailments Schemes have been demonstrated to
improve the efficiency of healthcare delivery [21] and improve clinical and humanistic outcomes [4].
Widespread implementation of a Minor Ailments Scheme in the Australian setting has the potential
to support community pharmacists in the provision of consistent, high-quality and appropriately
remunerated primary care for all patients, including those taking high-risk prescription medications.
There are other possible explanations for the results apart from suboptimal history-taking. In visits
where the medication history was investigated, just over half of the visits still failed to reach a preferred
outcome, despite staff being aware of the DOAC. These results may highlight knowledge deficiencies
in areas of DOAC management; however, further research is required to investigate this. There was a
large variation in the percentage of preferred outcomes achieved between the three cases. The preferred
outcome was most commonly achieved in the bruising scenario, followed by the drug interaction
scenario and the dyspepsia scenario. Bruising is a side effect of all OACs, whereas the drug interaction
and dyspepsia are DOAC-specific complications. Pharmacists have reported being more confident
counselling on VKAs [14] and, as bruising is a common side effect of warfarin, pharmacists may be
more likely to identify it as a side effect of all OACs. DOACs are also safer medications, potentially
leading to fewer investigations into drug interactions. Dyspepsia is an adverse effect of dabigatran,
which is the least used DOAC in Australia [22]. Therefore, it may be seldom seen in practice, which may
lead to pharmacists overlooking it as the cause.
There are several limitations to this study. Participation in this study was voluntary. Therefore,
there may have been a bias in pharmacy selection leading to more confident pharmacies choosing
to participate. A small number of pharmacies were involved in the study, and the findings are not
necessarily representative of Australian pharmacy practice. Utilisation of MSs is a well-documented
approach that avoids many of the biases that plague other methodologies [23]. However, it only
assesses a small number of individuals at a specific time. The impact of the business of the pharmacies
and the impact of the time spent with the MSs was not taken into consideration when interpreting
the results. Furthermore, patient outcomes are not assessed in this methodology. The true impact of
the management of these scenarios is unknown. Student MSs have been employed in previous studies
to carry out simulated scenarios in community pharmacies [15,16]. However, students have not been
validated as accurate and convincing MSs in the same way other groups have been. Previous research
has shown that MSs have difficulty maintaining the appropriate standard, leading to some data being
excluded [24]. Despite undergoing training, the student MSs may have inconsistently acted out the
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scenarios. Furthermore, the student MSs may not have been convincing as pseudo-patients. Therefore,
the MSs may have been identified more often than reported, potentially influencing the results. Lastly,
the recall bias of the MSs must be considered when interpreting the results. Previous research has
shown that MSs have an error rate of 10% when reporting data [25]. Five pharmacies out of the 14 did
not consent to audio-recording. Out of the pharmacies that did consent to audio recording, some of the
audio was poor quality and certain words were hard to understand. Therefore, many interactions
relied completely on the MS recalling the interaction.
The scenarios used have not been validated in practice for the purpose of MS visits, which may
influence the results. The scenarios may also have influenced the likelihood of a preferred outcome being
achieved. Two of the three scenarios were product requests. Previous research has demonstrated that
product-request scenarios are performed more poorly than symptom based scenarios [20]. Furthermore,
two of the three scenarios required a direct referral to a GP, whilst the third required an instruction to
visit a GP if symptoms continued. These scenarios could arguably be more difficult than scenarios that
do not require a GP referral, leading to inferior outcomes.
Future studies should look to expand this investigation to a wider range of pharmacies. Studies might
also investigate whether pharmacists have knowledge gaps regarding DOAC management, and investigate
the potential for improved pharmacy assistant training or a protocol-driven Minor Ailments Scheme to
improve preferred outcome rates.
5. Conclusions
The preferred outcome of the scenarios investigated was not consistently achieved when a
pharmacist was not involved in the interaction. Overall, pharmacy staff often failed to identify the
potential cause of the presenting complaint and therefore did not consistently reach the preferred
outcome. A complete history-taking process, including medication history, significantly improved
the outcome of the scenarios. The potential for strategies that support comprehensive pharmacist
involvement in OTC requests, including a formal protocol-driven Minor Ailments Scheme, could be
considered by professional organisations and/or pharmacy chains to ensure the provision of optimal
care to patients taking high-risk medications such as DOACs.
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